Response to the AIDS pandemic - A global health model

New England Journal of Medicine

Volumn 368, Issue 23, 2013, Pages 2210-2218

  Piot, Peter ^a   Quinn, Thomas C ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CIRCUMCISION; CONDOM USE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INTERNATIONAL COOPERATION; MORTALITY; PANDEMIC; PATIENT COMPLIANCE; PERINATAL INFECTION; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; RISK REDUCTION; SAFE SEX; UNITED NATIONS; VACCINATION; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 84878524128     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1201533     Document Type: Review

References (61)

1. Pneumocystis pneumonia - Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2.
2. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. MMWR Morb Mortal Wkly Rep 1981;30:305-8.
3. Piot P, Quinn TC, Taelman H, et al. Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet 1984;2:65-9.
4. Quinn TC, Mann JM, Curran JW, Piot P. AIDS in Africa: an epidemiologic paradigm. Science 1986;234:955-63.
5. Gallo RC, Montagnier L. The discovery of HIV as the cause of AIDS. N Engl J Med 2003;349:2283-5.
6. Piot P, Bartos M, Ghys PD, Walker N, Schwartländer B. The global impact of HIV/AIDS. Nature 2001;410:968-73.
7. World AIDS Day report 2011 - how to get to zero: Faster. Smarter. Better. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2011.
8. Global AIDS response progress reporting 2012. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2012.
9. Shiffman J. Has donor prioritization of HIV/AIDS displaced aid for other health issues? Health Policy Plan 2008;23:95-100.
10. El-Sadr WM, Abrams EJ. Scale-up of HIV care and treatment: can it transform healthcare services in resource-limited settings? AIDS 2007;21:Suppl 5:S65-S70.
11. Rasschaert F, Pirard M, Philips MP, et al. Positive spill-over effects of ART scale up on wider health systems development: evidence from Ethiopia and Malawi. J Int AIDS Soc 2011;14:Suppl 1:S3.
12. Harries AD, Zachariah R, Jahn A, Schouten EJ, Kamoto K. Scaling up antiretroviral therapy in Malawi - implications for managing other chronic diseases in resource-limited countries. J Acquir Immune Defic Syndr 2009;52:Suppl 1:S14-S16.
13. Lamptey P, Merson M, Piot P, Reddy KS, Dirks R. Informing the 2011 UN Session on Noncommunicable Diseases: applying lessons from the AIDS response. PLoS Med 2011;8(9):e1001086.
14. Global report: UNAIDS report on the global AIDS epidemic 2012. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2012.
15. AIDSinfo: epidemiological status. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2012 (http://www.unaids.org/en/dataanalysis/datatools/ aidsinfo/).
16. The 2010 national antenatal HIV and syphilis prevalence survey in South Africa. Pretoria: South Africa National Department of Health, 2011.
17. Beyrer C, Baral SD, van Griensven F. The global epidemiology of HIV infection among men who have sex with men. Lancet 2012;380:367-77.
18. Baral S, Beyrer C, Muessig K, et al. Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:538-49.
19. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008;372:1733-45.
20. MacPherson EE, Sadalaki J, Njoloma M, et al. Transactional sex and HIV: understanding the gendered structural drivers of HIV in fishing communities in Southern Malawi. J Int AIDS Soc 2012;15:Suppl 1:1-9.
21. Pandey A, Benara SK, Roy N, et al. Risk behaviour, sexually transmitted infections and HIV among long-distance truck drivers: a cross-sectional survey along national highways in India. AIDS 2008;22:Suppl 5:S81-S90.
22. Abebe Y, Schaap A, Mamo G, et al. HIV prevalence in 72,000 urban and rural male army recruits, Ethiopia, 1999-2000. Ethiop Med J 2003;41:Suppl 1:25-30.
23. Bezemer D, de Wolf F, Boerlijst MC, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS 2008;22:1071-7.
24. Bendavid E, Holmes C, Bhattacharya J, Miller G. HIV development assistance and adult mortality in Africa. JAMA 2012;307:2060-7.
25. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9.
26. Mills EJ, Barnighausen T, Negin J. HIV and aging - preparing for the challenges ahead. N Engl J Med 2012;366:1270-3.
27. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated 2013. Washington, DC: Department of Health and Human Services, 2012 (http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf).
28. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
29. European guidelines for treatment of HIV infected adults in Europe: version 6.1. Paris: European AIDS Clinical Society, 2012 (http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6. 1-2edition.pdf).
30. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2010 revision). Geneva: World Health Organization (http://whqlibdoc.who.int/publications/2010/9789241599764- eng.pdf).
31. Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2012.
32. HIV surveillance - United States, 1981-2008. MMWR Morb Mortal Wkly Rep 2011;60:689-93. [Erratum, MMWR Morb Mortal Wkly Rep 2011;60:852.]
33. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011;52:793-800.
34. Vital signs: HIV prevention through care and treatment - United States. MMWR Mortal Wkly Rep 2011;60:1618-23.
35. Micek MA, Gimbel-Sherr K, Baptista AJ, et al. Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Syndr 2009;52:397-405.
36. Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011;6(12):e28691.
37. Stoneburner RL, Low-Beer D. Population-level HIV declines and behavioral risk avoidance in Uganda. Science 2004;304:714-8. [Erratum, Science 2004;306:1477.]
38. Evaluation of the 100% condom programme in Thailand: case study. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2000.
39. The International Group on Analysis of Trends in HIV Prevalence and Behaviours in Young People in Countries Most Affected by HIV. Trends in HIV prevalence and sexual behaviour among young people aged 15-24 years in countries most affected by HIV. Sex Transm Infect 2010;86:Suppl 2:ii72-ii83. [Erratum, Sex Transm Infect 2011;87:8.]
40. Beasley R. Reducing harm: brief report. Washington, DC: Institute of Medicine of the National Academies, January 2010.
41. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Kazatchkine M, Sidibe M, Strathdee SA. Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 2010;376:551-63.
42. Gupta GR, Parkhurst JO, Ogden JA, Aggleton P, Mahal A. Structural approaches to HIV prevention. Lancet 2008;372:764-75.
43. Jan S, Ferrari G, Watts CH, et al. Economic evaluation of a combined microfinance and gender training intervention for the prevention of intimate partner violence in rural South Africa. Health Policy Plan 2011;26:366-72.
44. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet 2012;379:1320-9.
45. Gray RH, Li X, Kigozi G, et al. The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS 2007;21:845-50.
46. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2(11):e298.
47. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643-56.
48. Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS 2012;26:609-15.
49. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009;360:1298-309.
50. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74. [Erratum, Science 2011;333:524.]
51. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
52. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV-1 prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
53. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-34.
54. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-22.
55. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Presented at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 3-6, 2013. abstract.
56. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-9.
57. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341:394-402.
58. Piot P, Bartos M, Larson H, Zewdie D, Mane P. Coming to terms with complexity: a call to action for HIV prevention. Lancet 2008;372:845-59.
59. Quinn T, Serwadda D. Preparing for the future of HIV/AIDS in Africa - a shared responsibility: brief report. Washington, DC: Institute of Medicine of the National Academies, November 2010.
60. The aids2031 Consortium. AIDS: taking a long-term view. Upper Saddle River, NJ: FT Press, 2010.
61. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20.